Mike Nahorski

Dr. Mike Nahorski joined NeoGenomics as Director of Clinical & Scientific Alliances through the Inivata acquisition in 2021. Prior to this, he worked in Medical Affairs as a Regional Medical Science Liaison covering Northern Europe at Eli Lilly and Company. Dr Nahorski’s academic background is in the molecular genetics of cancer predisposition and pain disorders. He has 10+ years of academic experience prior to moving into industry and received his PhD at the University of Birmingham focusing on the the molecular mechanisms of inherited kidney cancer. Following this, Dr Nahorski worked at the University of Cambridge’s Institute of Medical Research, publishing 20+ articles in leading academic journals including Nature Genetics, Science and Cell Reports.